Structure-Activity Relationship Studies on 6-Chloro-1-phenylbenzazepines Leads to the Identification of a New Dopamine D1 Receptor Antagonist.
D1R
D5R
antagonist
benzazepine
dopamine
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
11 Aug 2023
11 Aug 2023
Historique:
received:
19
07
2023
revised:
30
07
2023
accepted:
31
07
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The 1-phenylbenzazepine template has yielded a number of D1R-like ligands, which, though useful as pharmacological tools, have significant drawbacks in terms of selectivity versus D5R as well as pharmacokinetic behavior. A number of 1-phenylbenzazepines contain a 6-chloro functional group, but extensive SAR studies around the 6-chloro-1-phenylbenzazepine framework have not been reported in the literature. To further understand the tolerance of the 6-chloro-1-phenylbenzazepine template for various substituent groups towards affinity and selectivity at D1R, we synthesized two series of analogs with structural variations at the C-7, C-8,
Identifiants
pubmed: 37630262
pii: molecules28166010
doi: 10.3390/molecules28166010
pmc: PMC10458514
pii:
doi:
Substances chimiques
1-phenylbenzazepine
0
Receptors, Dopamine D1
0
Amides
0
Benzazepines
0
Dopamine Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute of Health
ID : 1SC1DA049961
Références
Bioorg Med Chem Lett. 2020 Aug 15;30(16):127305
pubmed: 32631525
Br J Pharmacol. 2015 Jan;172(1):1-23
pubmed: 25671228
Eur J Pharmacol. 2003 Aug 8;474(2-3):137-40
pubmed: 12921854
Comput Biol Chem. 2019 Dec;83:107140
pubmed: 31715491
Schizophr Bull. 2013 May;39(3):564-74
pubmed: 22290266
Curr Opin Neurol. 2003 Dec;16 Suppl 2:S1-2
pubmed: 15129843
Front Pharmacol. 2020 Jul 14;11:1003
pubmed: 32765257
J Med Chem. 2005 Feb 10;48(3):680-93
pubmed: 15689153
Neuroscience. 2020 Jul 15;439:301-318
pubmed: 31349007
J Pharmacol Exp Ther. 1990 Feb;252(2):558-67
pubmed: 1968972
Drugs. 1997 Oct;54(4):634-50
pubmed: 9339965
Curr Opin Neurol. 2003 Dec;16 Suppl 2:S3-9
pubmed: 15129844
J Med Chem. 1982 Jun;25(6):697-703
pubmed: 6980283
Eur J Pharmacol. 1990 Jun 12;188(6):335-47
pubmed: 1973652
Neuropsychiatr Dis Treat. 2015 Jul 29;11:1859-75
pubmed: 26251602
Cell Res. 2021 May;31(5):593-596
pubmed: 33750903
J Med Chem. 2023 Jul 27;66(14):10060-10079
pubmed: 37421373
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
Neurosci Biobehav Rev. 2000 Jan;24(1):125-32
pubmed: 10654668
Med Res Rev. 2009 Mar;29(2):272-94
pubmed: 18642350
Behav Brain Res. 1991 Nov 26;45(2):117-24
pubmed: 1686397
Life Sci. 1983;33 Suppl 1:665-8
pubmed: 6607393
Neuropsychopharmacology. 2016 Jul;41(8):2072-81
pubmed: 26763483
Bioorg Chem. 2022 Oct;127:105953
pubmed: 35772367
Neurosci Lett. 2020 Aug 24;734:135151
pubmed: 32531529
Clin Exp Hypertens A. 1987;9(5-6):955-75
pubmed: 3304731
Neurol Ther. 2018 Dec;7(2):307-319
pubmed: 30361858
Nature. 2009 May 21;459(7245):356-63
pubmed: 19458711
J Pharmacol. 1984 Oct-Dec;15(4):401-14
pubmed: 6098788
Ideggyogy Sz. 2019 May 30;72(5-6):187-193
pubmed: 31241263
Br J Clin Pharmacol. 1987 Dec;24(6):721-7
pubmed: 2894216
Bioorg Med Chem Lett. 2020 Apr 15;30(8):127053
pubmed: 32107165
Physiol Rev. 1998 Jan;78(1):189-225
pubmed: 9457173